Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma

医学 来那度胺 Carfilzomib公司 达拉图穆马 梅尔法兰 多发性骨髓瘤 耐受性 内科学 硼替佐米 肿瘤科 地塞米松 蛋白酶体抑制剂 不利影响 外科
作者
Ola Landgren,Malin Hultcrantz,Benjamin Diamond,Alexander M. Lesokhin,Sham Mailankody,Hani Hassoun,Carlyn Tan,Urvi A. Shah,Sydney X. Lu,Meghan Salcedo,Kelly Werner,Jenna Rispoli,Julia Caple,Allison Sams,Dennis Verducci,Katie Jones,Isabel Concepcion,Ciardello Amanda,Aisara Chansakul,Julia Schlossman
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:7 (6): 862-862 被引量:93
标识
DOI:10.1001/jamaoncol.2021.0611
摘要

Recently, the benefit of adding daratumumab to the proteasome inhibitor-based, 3-drug combination of bortezomib, lenalidomide, and dexamethasone for patients with newly diagnosed multiple myeloma who underwent high-dose melphalan chemotherapy and autologous hemopoietic cell transplant was assessed. Here, we examine the addition of daratumumab to the second-generation proteasome inhibitor-based, 3-drug combination of carfilzomib, lenalidomide, and dexamethasone.To assess the safety and effectiveness of carfilzomib-lenalidomide-dexamethasone-daratumumab combination therapy for patients with newly diagnosed multiple myeloma, in the absence of high-dose melphalan chemotherapy and autologous hemopoietic cell transplant.Clinical and correlative pilot study at the Memorial Sloan Kettering Cancer Center in New York, New York. Patients with newly diagnosed multiple myeloma were enrolled between October 1, 2018, and November 15, 2019. The median follow-up from start of treatment was 20.3 months (95% CI, 19.2-21.9 months).Eight 28-day cycles with intravenous carfilzomib, 20/56 mg/m2 (days 1, 8, and 15); oral lenalidomide, 25 mg, (days 1-21); dexamethasone, 40 mg weekly, orally or intravenously (cycles 1-4), and 20 mg after cycle 4; and intravenous daratumumab, 16 mg/kg (days 1, 8, 15, and 22 [cycles 1-2]; days 1 and 15 [cycles 3-6]; and day 1 [cycles 7 and 8]).The primary end point was the minimal residual disease (MRD) rate, in the absence of high-dose melphalan chemotherapy and autologous hemopoietic cell transplant. Secondary end points included determining safety and tolerability, evaluating rates of clinical response per the International Myeloma Working Group, and estimating progression-free survival (PFS) and overall survival (OS) rates.Forty-one evaluable patients were enrolled (median age, 59 years; range, 30-70 years); 25 (61%) were female, and 20 (49%) had high-risk multiple myeloma. The primary end point (MRD negativity in the bone marrow; 10-5 sensitivity) was achieved in 29 of 41 patients (71%; 95% CI, 54%-83%), and therefore the trial was deemed successful. Median time to MRD negativity was 6 cycles (range, 1-8 cycles). Secondary end points of the overall response rate and the very good partial response or complete response rate were 100% (41 of 41 patients) and 95% (39 of 41 patients), respectively. At 11 months of the median follow-up, the 1-year PFS rate and the OS rate were 98% (95% CI, 93%-100%) and 100%, respectively. Most common (≥2 patients) grade 3 or 4 adverse events were neutropenia (12 patients [27%]), rash (4 patients [9%]), lung infection (3 patients [7%]), and increased alanine aminotransferase level (2 patients [4%]). There were no deaths.In this nonrandomized clinical trial, carfilzomib-lenalidomide-dexamethasone-daratumumab combination therapy was associated with high rates of MRD negativity in patients with newly diagnosed multiple myeloma and high rates of PFS.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
传奇3的应助被dadada采纳,获得10
1秒前
天天快乐的应助被Zhang采纳,获得10
1秒前
1秒前
张某完成签到,获得积分10
5秒前
5秒前
万能图书馆的应助被独一无二采纳,获得10
5秒前
mingtian发布了新的文献求助10
6秒前
秋的账号完成签到,获得积分10
7秒前
8秒前
yyx完成签到 ,获得积分10
8秒前
万能图书馆的应助被happy21采纳,获得10
9秒前
斯文败类的应助被毅诚菌采纳,获得10
9秒前
睿123456发布了新的文献求助10
10秒前
烟花的应助被优雅千风采纳,获得10
13秒前
dadada发布了新的文献求助10
14秒前
SciGPT的应助被小卢采纳,获得10
15秒前
牛牛完成签到 ,获得积分10
16秒前
搜集达人的应助被YU采纳,获得10
16秒前
16秒前
xiaofan1991完成签到,获得积分10
17秒前
17秒前
18秒前
我真不忙完成签到 ,获得积分10
19秒前
尊敬的晓绿完成签到 ,获得积分10
19秒前
20秒前
m123完成签到,获得积分10
20秒前
11发布了新的文献求助10
21秒前
秋风的应助被北风北风采纳,获得20
21秒前
22秒前
vevive发布了新的文献求助10
23秒前
泡芙完成签到 ,获得积分10
23秒前
在水一方发布了新的文献求助10
23秒前
lansing完成签到 ,获得积分10
24秒前
初景发布了新的文献求助10
24秒前
rookie_xiao完成签到,获得积分10
24秒前
睿123456完成签到,获得积分10
25秒前
香蕉觅云的应助被酒窝小羊采纳,获得10
25秒前
科研通AI6.2的应助被Summer采纳,获得10
25秒前
等待geduo发布了新的文献求助10
26秒前
独云完成签到,获得积分10
27秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189584
求助须知:如何正确求助?哪些是违规求助? 9576880
关于积分的说明 21849988
捐赠科研通 7787473
什么是DOI,文献DOI怎么找? 3435679
关于科研通互助平台的介绍 2559801
邀请新用户注册赠送积分活动 2482606